NO20016053L - IL-8 reseptor-antagonister - Google Patents

IL-8 reseptor-antagonister

Info

Publication number
NO20016053L
NO20016053L NO20016053A NO20016053A NO20016053L NO 20016053 L NO20016053 L NO 20016053L NO 20016053 A NO20016053 A NO 20016053A NO 20016053 A NO20016053 A NO 20016053A NO 20016053 L NO20016053 L NO 20016053L
Authority
NO
Norway
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Application number
NO20016053A
Other languages
English (en)
Other versions
NO20016053D0 (no
Inventor
Katherine Louisa Widdowson
Daniel Frank Veber
Anthony Joseph Jurewicz
Melvin C Rutledge
Robert Philip Hertzberg
Gregory Martin Benson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20016053L publication Critical patent/NO20016053L/no
Publication of NO20016053D0 publication Critical patent/NO20016053D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
NO20016053A 1999-06-16 2001-12-11 IL-8 reseptor-antagonister NO20016053D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13967599P 1999-06-16 1999-06-16
PCT/US2000/016499 WO2000076495A1 (en) 1999-06-16 2000-06-15 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
NO20016053L true NO20016053L (no) 2001-12-11
NO20016053D0 NO20016053D0 (no) 2001-12-11

Family

ID=22487790

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016053A NO20016053D0 (no) 1999-06-16 2001-12-11 IL-8 reseptor-antagonister

Country Status (20)

Country Link
EP (1) EP1185261A4 (no)
JP (1) JP2003501459A (no)
KR (1) KR20020010709A (no)
CN (1) CN1355697A (no)
AR (1) AR030391A1 (no)
AU (1) AU766083B2 (no)
BR (1) BR0010802A (no)
CA (1) CA2377341A1 (no)
CO (1) CO5200760A1 (no)
CZ (1) CZ20014471A3 (no)
HK (1) HK1044483A1 (no)
HU (1) HUP0201571A3 (no)
IL (1) IL145761A0 (no)
MX (1) MXPA01013004A (no)
NO (1) NO20016053D0 (no)
NZ (1) NZ514695A (no)
PL (1) PL352232A1 (no)
TR (1) TR200103680T2 (no)
WO (1) WO2000076495A1 (no)
ZA (1) ZA200109479B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
IL166040A0 (en) * 2002-08-01 2006-01-15 Neurosearch As Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1745032B1 (en) * 2004-05-12 2013-07-31 Merck Sharp & Dohme Corp. CXCR1 and CXCR2 chemokine antagonists
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2006047302A1 (en) 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
WO2006089871A2 (en) * 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
US7728008B2 (en) 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE602006020871D1 (de) 2005-06-27 2011-05-05 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
EP1899299B1 (en) 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008184403A (ja) * 2007-01-29 2008-08-14 Japan Health Science Foundation 新規ｃ型肝炎ウイルス阻害剤
KR100982661B1 (ko) * 2008-04-22 2010-09-17 전남대학교산학협력단 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및이를 이용한 말라리아 치료방법
KR100970940B1 (ko) * 2010-05-03 2010-07-20 전남대학교산학협력단 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로 함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및 이를 이용한 말라리아 치료방법
US10093617B1 (en) * 2015-10-30 2018-10-09 Sumitomo Chemical Company, Limited Method for producing 2-amino-4-substituted phenol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
AU6035899A (en) * 1998-09-18 2000-04-10 Smithkline Beecham Corporation Cxcr2 inhibitors and pmn adhesion and t-cell chemotaxis

Also Published As

Publication number Publication date
CO5200760A1 (es) 2002-09-27
HK1044483A1 (zh) 2002-10-25
WO2000076495A1 (en) 2000-12-21
TR200103680T2 (tr) 2002-07-22
HUP0201571A3 (en) 2002-11-28
ZA200109479B (en) 2002-11-18
KR20020010709A (ko) 2002-02-04
CZ20014471A3 (cs) 2002-08-14
JP2003501459A (ja) 2003-01-14
PL352232A1 (en) 2003-08-11
HUP0201571A2 (en) 2002-08-28
AU766083B2 (en) 2003-10-09
EP1185261A1 (en) 2002-03-13
AU5741300A (en) 2001-01-02
IL145761A0 (en) 2002-07-25
NO20016053D0 (no) 2001-12-11
MXPA01013004A (es) 2002-07-30
CA2377341A1 (en) 2000-12-21
BR0010802A (pt) 2002-02-19
NZ514695A (en) 2004-05-28
EP1185261A4 (en) 2004-02-25
AR030391A1 (es) 2003-08-20
CN1355697A (zh) 2002-06-26

Similar Documents

Publication Publication Date Title
NO20001100D0 (no) IL-8 reseptorantagonister
NO20025754D0 (no) IL-8 Reseptor-antagonister
DE60216229D1 (de) Il-8-rezeptorantagonisten
NO20016053D0 (no) IL-8 reseptor-antagonister
ATE299698T1 (de) Il-8 rezeptor antagonisten
DE60126480D1 (de) Il-8 rezeptor-antagonisten
NO20016052D0 (no) IL-8-reseptor-antagonister
DE69838874D1 (de) Il-8 rezeptor-antagonisten
MA25739A1 (fr) Antagonistes recepteurs il-8
DK1180028T3 (da) IL-8-receptorantagonister
ATE303370T1 (de) Il-8 rezeptor antagonisten
DE69824837D1 (de) Il-8-rezeptor-antagonisten
NO20015774D0 (no) IL-8 reseptorantagonister
NO20024367D0 (no) IL-8 reseptorantagonister
NO20016102L (no) IL-8 reseptorantagonister
NO20016065L (no) IL-8-reseptor-antagonister
NO20024366L (no) IL-8 reseptorantagonister
NO20010353L (no) IL-8 reseptor-antagonist
SE0003996D0 (sv) Receptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application